Norge - norsk - Statens legemiddelverk

2care4 - solifenacinsuksinat - tablett, filmdrasjert - 5 mg

Norge - norsk - Statens legemiddelverk

orifarm as - solifenacinsuksinat - tablett, filmdrasjert - 5 mg

Norge - norsk - Statens legemiddelverk

2care4 - solifenacinsuksinat - tablett, filmdrasjert - 10 mg

Norge - norsk - Statens legemiddelverk

orifarm as - solifenacinsuksinat - tablett, filmdrasjert - 10 mg

Norge - norsk - Statens legemiddelverk

abbvie as - botulinumtoksin type a - pulver til injeksjonsvæske, oppløsning

Den europeiske union - norsk - EMA (European Medicines Agency)

alexion europe sas - ravulizumab - hemoglobinuri, paroksysmal - selektive immunosuppressiva - paroxysmal nocturnal haemoglobinuria (pnh)ultomiris is indicated in the treatment of adult and paediatric patients with a body weight of 10 kg or above with pnh:- in patients with haemolysis with clinical symptom(s) indicative of high disease activity. - in patients who are clinically stable after having been treated with eculizumab for at least the past 6 months (see section 5. atypical haemolytic uremic syndrome (ahus)ultomiris is indicated in the treatment of patients with a body weight of 10 kg or above with ahus who are complement inhibitor treatment-naïve or have received eculizumab for at least 3 months and have evidence of response to eculizumab (see section 5. generalized myasthenia gravis (gmg)ultomiris is indicated as an add-on to standard therapy for the treatment of adult patients with gmg who are anti-acetylcholine receptor (achr) antibody-positive. neuromyelitis optica spectrum disorder (nmosd)ultomiris is indicated in the treatment of adult patients with nmosd who are anti-aquaporin 4 (aqp4) antibody-positive (see section 5. ultomiris is indicated in the treatment of adult patients with paroxysmal nocturnal haemoglobinuria (pnh):- in patients with haemolysis with clinical symptom(s) indicative of high disease activity. - in patients who are clinically stable after having been treated with eculizumab for at least the past 6 months. ultomiris is indicated in the treatment of adult patients with atypical haemolytic uremic syndrome (ahus) who are complement inhibitor treatment-naïve or have received eculizumab for at least 3 months and have evidence of response to eculizumab.

Norge - norsk - Statens legemiddelverk

ethypharm (2) - glykopyrroniumbromid - injeksjonsvæske, oppløsning - 200 mikrog/ ml

Norge - norsk - Statens legemiddelverk

bioq pharma b.v. - ropivakainhydrokloridmonohydrat - infusjonsvæske, oppløsning i administreringssystem - 2 mg/ ml

Norge - norsk - Statens legemiddelverk

paranova as - sevofluran - væske til inhalasjonsdamp

Norge - norsk - Statens legemiddelverk

accord healthcare b.v. - solifenacinsuksinat - tablett, filmdrasjert - 5 mg